Hospital patients who receive antibiotic treatment may face about a 20% risk of a related adverse event, if the results of a new study from Johns Hopkins University researchers can be generalized.
One study found that antibiotic use was the main factor driving differences.
A study yesterday in BMC Infectious Diseases indicates that piperacillin/tazobactam (PTZ) is effective in treating healthcare-associated urinary tract infection (UTI) caused by extended-spectrum, beta-lactamase-producing Escherichia coli (ESBL-EC), a type of infection for which therapeutic options are limited.
A review of hospital-onset Pseudomonas aeruginosa infections in the United States found that the mortality from multidrug-resistant P aeruginosa (MDR-PSA) is nearly twice that of non-MDR-PSA infections.
Implementation of an antimicrobial stewardship program (ASP) at a rural community hospital in Georgia significantly reduced Clostridium difficile infections (CDIs), antimicrobial use, and overall drug costs, researchers reported yesterday in the American Journal of Infection Control.
A phase 2 trial of the novel antibiotic ridinilazole in adults with Clostridium difficile infections showed that it performed better than vancomycin, one of three drugs used to routinely treat infections, and was well tolerated, with a similar adverse event profile.
Within 2 months of admission, 29% of C diff patients died, compared with 14% of the control group.
A 16-study meta-analysis finds about a 50% higher risk tied to anti-reflux drugs.
More details emerged today on President Donald Trump's proposed budget, including plans to drastically cut research grant funding to the National Institutes of Health (NIH) in the current fiscal year, which ends in October.
In a study that expands on an earlier analysis, screening of blood donations in Puerto Rico last spring and summer found a 13% incidence of Zika virus, according to a study yesterday in Emerging Infectious Diseases.
